Hostname: page-component-788cddb947-nxk7g Total loading time: 0 Render date: 2024-10-07T15:44:34.889Z Has data issue: false hasContentIssue false

Methoxphenidine (1-(1-(2-methoxyphenyl)-2-phenylethyl) Piperidine; 2-meo-diphenidine): Preliminary Data On Chemical, Pharmacological and Clinical Effects

Published online by Cambridge University Press:  15 April 2020

L. Orsolini
Affiliation:
United Hospital and Academic Department of Experimental and Clinical Medicine and School of Life and Medical Sciences, Università Politecnica delle Marche and University of Hertfordshire, Ancona and Hatfield Herts UK, Italy
G. Papanti
Affiliation:
School of Life and Medical Sciences, Medical School of Trieste and University of Hertfordshire, Trieste and Hatfield Herts UK, Italy
F. Professor Schifano
Affiliation:
School of Life and Medical Sciences, University of Hertfordshire, Hatfield Herts, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Due to the growing demand for alternatives to arylcyclohexylamine-type substances, a new dissociative and hallucinogenic drug, Methoxphenidine (2-MXP; (±)-1-[1-(2-methoxyphenyl)-2-phenylethyl] piperidine; 2-Meo-diphenidine) has been recently appeared in the drug market. Very little information is still available in the scientific literature on this new compound. Recently, it was identified in UK a death associated to this drug. Aims of this paper is here to provide a comprehensive overview on pharmacology, chemical and psychoactive effects of 2-MXP.

Methods

Given the limited available evidence, data in scientific literature were integrated with a qualitative assessment of online drug-user-oriented fora and blogs. A Multilanguage internet snapshot study was undertaken by typing a specified set of keywords on Google® and Yahoo® search engines.

Results

2-MXP, structurally analogue to diphenidine, was introduced in the market as the replacement to illegal methoxetamine (MXE). Anecdotal reports suggest 2-MXP has greater oral potency. 2-MXP may act as a selected NMDA antagonist and probably it may have a dopamine reuptake inhibitor action, according to the effects reported by online drug users. Currently, there are not peer-reviewed epidemiological, toxicological, pharmacological and clinical data about recreational use of 2-MXP. According to online drug users, it induces dissociation, visual effects and seems to be associated with seizures at heavy dosages.

Conclusions

There is the need of further studies on its toxicological and pharmacological pattern as well as investigate its potential psychotropic and adverse effects, in order to confirm and better describe its recreational use.

Type
Article: 1046
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.